1-7 of 7
Miriam Y Kim, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-133891
Published: 2020
Journal Articles

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Elisa De Togni, BA, Miriam Y Kim, MD, Matt L Cooper, PhD, Julie Ritchey, Julie O'Neal, PhD, Jessica Niswonger, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2205.
https://doi.org/10.1182/blood-2018-99-113438
Published: 2018
Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 1000.
https://doi.org/10.1182/blood.V128.22.1000.1000
Published: 2016
Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 652.
https://doi.org/10.1182/blood.V128.22.652.652
Published: 2016
Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 766.
https://doi.org/10.1182/blood.V128.22.766.766
Published: 2016
Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 852.
https://doi.org/10.1182/blood.V126.23.852.852
Published: 2015
Journal Articles

Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis

Sikander Ailawadhi, MD, Dongyun Yang, PhD, Gaurav Patel, MSHA, Yin Zhang, MD, Ibrahim T. Aldoss, MBBS, Miriam Y. Kim, MD, Asher Chanan-Khan, MD
Journal: Blood
Blood (2011) 118 (21): 845.
https://doi.org/10.1182/blood.V118.21.845.845
Published: 2011